Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
VISEN Pharmaceuticals ( (HK:2561) ) just unveiled an announcement.
VISEN Pharmaceuticals held its Annual General Meeting on June 27, 2025, where all proposed resolutions were unanimously approved by shareholders. Key outcomes included the retirement of non-executive directors, a change in the chairman of the board, and a reconfiguration of the nomination committee. Additionally, the company ratified a commercial supply agreement with Ascendis Pharma Europe A/S and approved the grant of award shares to an executive director, indicating strategic moves to strengthen its leadership and operational framework.
More about VISEN Pharmaceuticals
VISEN Pharmaceuticals is a company incorporated in the Cayman Islands, operating within the pharmaceutical industry. It is listed on the Hong Kong Stock Exchange and focuses on the development and commercialization of innovative therapies.
Average Trading Volume: 74,340
For a thorough assessment of 2561 stock, go to TipRanks’ Stock Analysis page.